Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.32 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.32 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.32 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.32 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.32 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.32 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.32 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | THRA | P10827 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 4/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949953 | 0.86 | SLC6A4 (0.32) | LMNAALOX5CHRM1SLC6A2GABRA1 | |
| SCHEMBL2019552 | 0.86 | SLC6A4 (0.32) | LMNAALOX5CHRM1SLC6A2GABRA1 | |
| Cadaverine Tartrate SCHEMBL2026631 | 0.76 | ALOX5 (0.41) | KDM4ELMNAHIF1ABLMPMP22 | |
| Cadaverine Tartrate SCHEMBL2026630 | 0.76 | ALOX5 (0.41) | KDM4ELMNAHIF1ABLMPMP22 | |
| SCHEMBL12263503 | 0.69 | MAPT (0.39) | KDM4EPOLBMAPTHSD17B10ALDH1A1 | |
| Cadaverine Tartrate SCHEMBL27715535 | 0.68 | LMNA (0.48) | KDM4ELMNAHIF1AMAPK1ADRA2A | |
| Cadaverine Tartrate SCHEMBL9113235 | 0.68 | LMNA (0.48) | KDM4ELMNAHIF1AMAPK1ADRA2A | |
| SCHEMBL12261853 | 0.67 | SLC6A4 (0.35) | — | |
| SCHEMBL12087046 | 0.67 | SLC6A4 (0.35) | — | |
| Tartaric Acid SCHEMBL29752496 | 0.66 | TSHR (0.53) | KDM4ELMNAHIF1ATSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110009482-A1 | METHODS OF TREATING COPD | SCHERING CORPORATION (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | CCL2, CCR1, CXCR1 | ADRB2 2490/4885CHRM2 3512/4885CHRM1 2939/4885 |
| US-20110009482-A1 | METHODS OF TREATING COPD | CXCR2, AGTR2, LTB4R2 | ADRB2 8/4885CHRM2 147/4885CHRM1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.